Synakis has created a vitreous substitute to transform the treatment of retinal detachment which use vitreous substitutes.
Business Model:
Revenue: $0
Employees: 1-10
Address:
City: Toronto
State: Ontario
Zip:
Country: Canada
Synakis patented a biodegradable hydrogel vitreous substitute that is injectable, non-cytotoxic in vitro and in vivo, low-swelling, stable, and optically transparent with a refractive index and density similar to those of the native vitreous.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|